India’s generics exports expanding 22% per year

25 Oct 2017

Country accounts for over 20% of global production with $20 billion exports forecast by 2020.

The India Brand Equity foundation (IBEF) and the Pharmaceuticals Export Promotion Council (PHARMEXCIL) provide an update on the country’s generics market as the world’s pharma industry meets for its annual exposition at CPhI Worldview in Frankfurt. Data confirms that the country’s branded generic sector accounts for a massive 98% of the marketplace – reaching a value in excess of US$12 billion – with India remaining the world’s leading exporter.

India’s generics exports expanding 22% per year

PHARMEXCIL confidently forecast that generic exports are now growing at around 22% per year, with India accounting for around 20-22% of the world’s production, covering more than 60,000 brands and 60 therapeutic classes.

Total exports of pharmaceuticals – including APIs, generics and alternative systems of medicine – climbed to $16.84 billion during 2016-17, with 34% and 15% supplied to the US and EU markets respectively.

Shri Ravi Udaya Bhaskar, Director General, Pharmexcil, commented: “A key driver for this growth is India’s extensive product portfolio, which provides the capability to manage and treat any ATC (Anatomical therapy classification) – to the same quality as the innovators – at highly affordable costs.”

According to the analysis India has provided up to 50% of new DMFs and between a quarter and a third of new ANDAs each year for the past decade – in addition to supporting hundreds of ANDAs filed by US and EU companies. The country was also credited with between 30% and 50% of the total CEPS between 2013 and 2017, including being the first to file generic drugs in the EU and the US. Consequently, India now boasts 7 companies amongst the top 20 global generic organisations.

Shri Ravi Udaya Bhaskar, added:“The industry has been working diligently towards enhancing its capabilities and strengths. This includes its more than 950 colleges, which deliver over 90,000 pharmaceutical graduates per year, of which, 30,000 have completed master’s degrees. Moreover, Government’s policies are directed at increasing infrastructure facilities to help enable manufacturing to reach its highest potential – with pharma exports expected to reach $20 billion by 2020.”

Read More

Related news

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

9 Sep 2019

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Read more 
Take part in pharma’s largest reputation survey

Take part in pharma’s largest reputation survey

6 Sep 2019

Use your voice to shape CPhI Worldwide's third annual global survey of the major trends, changes and developments in the industry.

Read more 
Meet Avivia / Excipia at booth B56 Hall 12.1 CPhI Frankfurt 2019

Meet Avivia / Excipia at booth B56 Hall 12.1 CPhI Frankfurt 2019

29 Aug 2019

Meet Avivia at booth B56 Hall 12.1 CPhI Frankfurt 2019

Read more 
Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

16 Aug 2019

Pipeline of new drugs has helped drive increased innovation in packaging and drug delivery devices.

Read more 
Growing domestic manufacturing creates new opportunities for international pharma in the Middle East

Growing domestic manufacturing creates new opportunities for international pharma in the Middle East

5 Aug 2019

Opportunities abound at CPhI MEA and experts anticipate regional generic companies acting as CMOs for international companies looking to enter the region.

Read more 
Drive for generics sees Korea increasingly attractive to international pharma

Drive for generics sees Korea increasingly attractive to international pharma

31 Jul 2019

Korean companies are opening more facilities overseas and using CPhI Korea to look for new international partners.

Read more 
Huge CPhI & P-MEC China a direct result of surging manufacturing

Huge CPhI & P-MEC China a direct result of surging manufacturing

22 Jul 2019

Great Hall of China: Informa adds additional capacity to Asia’s largest pharma event with record 66,000+ visits from 141 countries.

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more 
Piramal expands its high potency API capability

Piramal expands its high potency API capability

25 Jun 2019

Becomes one of only a few companies in the contract development and manufacturing market that can produce HPAPIs at such low OELs.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more